HEPZATO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hepzato, and when can generic versions of Hepzato launch?
Hepzato is a drug marketed by Delcath Systems Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has twenty-six patent family members in nine countries.
The generic ingredient in HEPZATO is melphalan hydrochloride. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hepzato
A generic version of HEPZATO was approved as melphalan hydrochloride by MYLAN INSTITUTIONAL on June 9th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEPZATO?
- What are the global sales for HEPZATO?
- What is Average Wholesale Price for HEPZATO?
Summary for HEPZATO
International Patents: | 26 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | HEPZATO at DailyMed |
US Patents and Regulatory Information for HEPZATO
HEPZATO is protected by eleven US patents and two FDA Regulatory Exclusivities.
Patents protecting HEPZATO
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING A SUBJECT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A PERCUTANEOUS HEPATIC PERFUSION PROCEDURE FOR TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting HEPZATO
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
AS A LIVER-DIRECTED TREATMENT FOR ADULT PATIENTS WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES AFFECTING LESS THAN 50% OF THE LIVER AND NO EXTRAHEPATIC DISEASE OR EXTRAHEPATIC DISEASE LIMITED TO THE BONE, LYMPH NODES, SUBCUTANEOUS TISSUES, OR LUNG THAT IS AMENABLE TO RESECTION OR RADIATION
Exclusivity Expiration: ⤷ Sign Up
International Patents for HEPZATO
See the table below for patents covering HEPZATO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E046954 | ⤷ Sign Up | |
European Patent Office | 3360588 | FILTRE ET APPAREIL CADRE ET PROCÉDÉ D'UTILISATION (FILTER AND FRAME APPARATUS AND METHOD OF USE) | ⤷ Sign Up |
European Patent Office | 3590561 | APPAREIL POUR RETIRER DES COMPOSÉS DE CHIMIOTHÉRAPIE À PARTIR DU SANG (APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD) | ⤷ Sign Up |
Denmark | 3603693 | ⤷ Sign Up | |
Spain | 2728280 | ⤷ Sign Up | |
European Patent Office | 3238762 | APPAREIL FILTRANT ET CADRE, ET PROCÉDÉ D'UTILISATION (FILTER AND FRAME APPARATUS AND METHOD OF USE) | ⤷ Sign Up |
Spain | 2913795 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for HEPZATO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2701720 | CA 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | 122023000007 | Germany | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817 |
2701720 | 23C1000 | France | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2701720 | 301206 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2701720 | CR 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | 3/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |